This review briefly summarizes the current understanding of zinc dyshomeostasis in cancer, and discusses the potential roles of zinc or zinc transporters in cancer therapy. The review is focused on isotopically natural zinc and does not discuss any possible isotope effects.

This review reports isotopic data for Zn uptake-efflux experiments using a human breast cancer cell line. MDA-MB-231 cell line was used as a model for triple receptor negative breast cancer. Zn isotopic composition in clinical samples of breast cancer tissue are analyzed relative to healthy tissue. 

This review reports the measurements of the ratio of stable isotopes of zinc (δ66Zn) in bioapatite (bone and dental enamel) of animals and demonstrates that δ66Zn values in both bone and enamel allow a clear distinction between carnivores and herbivores. 

This review addresses that zinc supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with other drugs, and that mutant p53 proteins undergo protein misfolding that can be counteracted by zinc.

This review consolidates the knowledge on the critical functions of cellular zinc signaling and underscores potential molecular pathways linking zinc metabolism to disease progression, with a special focus on cancer. The review also compiles a summary of clinical trials involving zinc ions.

The aim of this study was to investigate whether the zinc chelating activity of EA contributed to its anti-angiogenic effect.

This publication presents a comparison of activation patterns of microglia/macrophage population and systemic inflammation indices in rats with 6-Hydroxydopamine (6-OHDA)- and Lipopolysaccharide (LPS)-induced animal models of Parkinson's Disease. This is essential for maximizing the translation of their potential to the clinic, as well as for developing putative anti-inflammatory neuroprotective agents.

Neuroinflammation is associated with the impairment of blood–brain barrier and leakage of inflammatory mediators into the periphery with developing systemic inflammatory responses. Systemic inflammation is considered one of the therapeutic targets for AD treatment that necessitates in-depth study of this phenomenon in appropriate non-transgenic animal models. This publication discusses inflammation as one of the therapeutic targets for treatment of Alzheimer's disease (AD.)

The aim of this mini-review is to present an overview of the current knowledge of the metallome found within specific brain cells (oligodendrocytes, astrocytes, microglia, and neurons), as revealed by direct elemental mapping techniques. Iron (Fe), Copper (Cu), and Zinc (Zn) are necessary for healthy brain function. Despite the known importance of metal ions for both brain health and disease, the metallome that exists within specific types of brain cells is yet to be fully characterised.

In her TED Talk, neuroscientist Sandrine Thuret explains that adults can indeed grow new brain cells primarily in the hippocampus, a region crucial for learning, memory, mood, and emotion. She presents research showing that neurogenesis is linked to improved memory and mood, and that factors such as learning, physical activity (especially running), and certain dietary habits (like calorie restriction, intermittent fasting, and consuming foods rich in flavonoids and omega-3 fatty acids) can boost the production of new neurons. Conversely, stress, sleep deprivation, aging, high saturated fat intake, and excessive alcohol consumption can reduce neurogenesis. Thuret emphasizes that lifestyle choices can significantly influence brain health and encourages individuals to take charge of their neurogenesis to support cognitive function and emotional well-being as they age.

Metallomix combines biochemistry and biophysics to leverage the body’s "metallome," and its broader molecular networks and other "omes" — such as the genome, proteome and microbiome.

The natural abundance of heavy stable isotopes is now of considerable importance in many research fields, including human physiology. In fact, it varies between tissues and metabolites due to isotope effects in biological processes, that is, isotope discriminations between heavy and light isotopic forms during enzyme or transporter activity. The metabolic deregulation associated with many diseases leads to alterations in metabolic fluxes, resulting in changes in isotope abundance. This review summarizes the current knowledge on changes in natural isotope composition in samples (including various tissues, hair, plasma, saliva) found in patients compared to controls, caused by human diseases.

In this interview, Dr. Cowan discusses his unconventional views on cancer and health, challenging mainstream medical assumptions by emphasizing the role of water biology in cellular health and disease, specifically the concept of "exclusion zone" water. He argues that cancer is not fundamentally a genetic disease, but rather a result of environmental toxins and disruptions in the body's water structure, suggesting that tumors act as the body's way of isolating and managing toxins, rather than being the primary disease itself. Dr. Cowan advocates for holistic cancer treatments that focus on detoxification, dietary changes (such as ketogenic diets and deuterium-depleted water), and minimizing exposure to environmental poisons and electromagnetic fields. He also questions the efficacy of conventional cancer screening and treatments, urging a reevaluation of basic biological assumptions and a greater focus on supporting the body's natural healing processes.

This economic evaluation study used data from public and proprietary sources to estimate the mean cost of developing a new drug from 2000 to 2018, which was $172.7 million (2018 dollars) but increased to $515.8 million when cost of failures was included and to $879.3 million when both drug development failure and capital costs were included. The ratio of R&D spending to total sales increased from 11.9% to 17.7% from 2008 to 2019.

The article profiles the groundbreaking work of Max Temnik, a chemistry PhD and entrepreneur, and Dr. Santosh Kesari, a leading neuro-oncologist, who are developing a potentially transformative, disease-modifying drug for Parkinson’s disease through their company, Metallomix Inc. (formerly Nomax Therapeutics). Temnik’s innovative approach centers on isotope-selective modulation of homeostasis (ISM), a process that targets the subatomic changes in human biomolecules associated with aging and disease. Preclinical studies in Parkinson’s-induced rodent models have shown that ISM treatment can prevent the degeneration of dopamine neurons and may even stimulate neurogenesis, offering hope for a true disease-modifying therapy. With encouraging safety results, the team is now seeking further investment to advance to full-size clinical trials, aiming to bring a therapy to market that could fundamentally alter the course of Parkinson’s disease and improve quality of life for millions worldwide.